SpyGlass Pharma, Inc. Common Stock (SGP )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SGP
- Company SpyGlass Pharma, Inc. Common Stock
- Price $26.4
- Changes Percentage 65
- Change 10.40
- Day Low $20.16
- Day High $32.44
- Year High $32.44
- Year Low $20.16
- Market Cap $842,454,703
- Price Avg 50 EMA (D) $26.4
- Price Avg 200 EMA (D) $26.4
- Exchange NASDAQ
- Volume 1,179,874
- Average Volume 1,193,200
- Open $24
- Previous Close $16
- EPS 0
- PE 0.00
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $31,911,163
Company brief: SPYGLASS PHARMA, INC. COMMON STOCK (SGP )
- Healthcare
- Biotechnology
- Patrick Mooney
- http://www.spyglasspharma.com
- US
- N/A
- 01-08-2008
- US85220G1094
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.